Request Demo

Last update 23 Jan 2025

EBV viremia

Last update 23 Jan 2025

Basic Info

Synonyms

EBV viraemia, EBV viremia

Introduction-

Drugs associated with EBV viremia

Tabelecleucel

Target

EBV Protein

Mechanism

EBV Protein inhibitors [+1]

Active Org.

Atara Biotherapeutics, Inc. [+1]

Originator Org.

Memorial Sloan Kettering Cancer Center

Active Indication

Inactive Indication

EBV viremia [+2]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

EU [+3]

First Approval Date16 Dec 2022

EBV-CTL(Memorial Sloan-Kettering Cancer Center)

Target

CD19

Mechanism

CD19 modulators

Active Org.-

Originator Org.

Memorial Sloan Kettering Cancer Center

Active Indication-

Inactive Indication

EBV viremia [+2]

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with EBV viremia

NCT06681025

/ CompletedNot Applicable

An Observational, Multi-center, Prospective and Retrospective Clinical Study to Evaluate the Performance of the NeuMoDx™ EBV Quant Assay 2.0 on the NeuMoDx™ Molecular Systems in Immunocompromised Transplant Patients

The NeuMoDx EBV Quant Assay 2.0 study is a multi-center, observational clinical investigation designed to evaluate the performance of the NeuMoDx EBV Quant Assay 2.0 in quantifying Epstein-Barr virus (EBV) DNA levels in plasma samples from immunocompromised transplant patients. The study compares the NeuMoDx EBV assay's performance against an FDA-cleared comparator assay under routine clinical use conditions, utilizing both the NeuMoDx™ 96 and NeuMoDx™ 288 Molecular Systems. The aim is to demonstrate the quantitative concordance and clinical utility of the assay in monitoring EBV DNA levels as part of patient management.

Start Date31 Aug 2022

Sponsor / Collaborator

QIAGEN Gaithersburg, Inc.

NCT04189835

/ Active, not recruitingNot ApplicableIIT

EVITA Study - Epstein-Barr Virus Infection MoniToring in RenAl Transplant Recipients - Early Identification of Increased Risk of Infection and Cancer for Individualised Immunosuppression.

Transplant recipients are treated with immunosuppressive drugs to avoid rejection of the transplanted organ. As the medication impairs the immune response, it also increases the risk of serious infections and cancer in transplant recipients compared with the general population.
Previous studies have shown a close association between Epstein-Barr virus (EBV) and post transplant lymphoproliferative disorder (PTLD), with frequent demonstration of the virus in lesional tissues. Transplant recipients without evidence of EBV infection prior to transplantation (EBV seronegative) are at particularly high risk of developing PTLD. Other risk factors include a high viral load. As part of a preventive approach against PTLD, several transplantation units now monitor the occurrence of EBV DNAemia after transplantation. However, there is little evidence to guide this strategy; nor is there consensus concerning either the best specimen to use for EBV analysis (whole blood or plasma) or the appropriate clinical action to take if EBV DNAemia is detected.
Our aim is to estimate the incidence and clinical consequences of Epstein-Barr virus (EBV) DNAemia in whole blood and plasma in renal transplant recipients, and to determine if persistence of EBV DNAemia can predict excessive immunosuppression as indicated by the incidence of infections requiring hospitalisation, EBV driven PTLD and mortality.

Start Date03 Jan 2020

Sponsor / Collaborator

University of Aarhus

[+2]

EUCTR2014-004817-98-GR

/ Not yet recruitingPhase 1/2IIT

Administration of Rapidly Generated Multivirus-Specific Cytotoxic TLymphocytes for the Treatment of CMV, EBV, and BK virus Infections post Allogeneic Stem Cell Transplant - Tri-VSTs-001

Start Date25 Jun 2019

Sponsor / Collaborator-

100 Clinical Results associated with EBV viremia

100 Translational Medicine associated with EBV viremia

0 Patents (Medical) associated with EBV viremia

343

Literatures (Medical) associated with EBV viremia

01 Jan 2025·Journal of Gastroenterology

The landscape of 142 Epstein–Barr viral whole genomes in gastric cancer

Article

Author: Kataoka, Hiromi ; Murata, Takayuki ; Goto, Kimitoshi ; Kato, Seiichi ; Arai, Haruto ; Akutsu, Yuta ; Yatabe, Yasushi ; Kimura, Hiroshi ; Khine, Htet Thiri ; Nakaguro, Masato ; Kojima, Yuki ; Kawada, Jun-Ichi ; Kodera, Yasuhiro ; Hamada, Motoharu ; Naruse, Azumi ; Satou, Akira ; Inagaki, Hiroshi ; Torii, Yuka ; Kawada, Jun-ichi ; Okuno, Yusuke ; Takiguchi, Shuji

BACKGROUNDA substantial portion of gastric cancer (GC) is linked to Epstein-Barr virus (EBV) infection. The characteristics of this viral genome, such as specific viral strains and large structural variations, influence the progression of diseases like nasopharyngeal carcinoma and hematological malignancy. However, the EBV genomes from GC have not been thoroughly characterized.METHODSOur study involved 849 consecutive GC patients diagnosed at Nagoya City University Hospital, Japan (NCU cohort). We detected EBV from formalin-fixed, paraffin-embedded sections using a novel direct PCR-based rapid detection method. Additionally, we analyzed 142 EBV whole genomes (125 newly sequenced) from GC, comparing them with 205 genomes from other EBV-associated diseases.RESULTSWe identified 32 (3.8%) patients associated with EBVaGC in the NCU cohort. Moreover, the direct PCR identified several GC specimens containing EBV-infected lymphocytes or their follicles. The dominant viral strain in GC was type 1 EBV, prevalent in most parts of the world, and no GC-specific strain was identified. We found no significant associations between single-nucleotide variants in the viral genome and GC. Structural variations of the EBV genome were infrequent in GC (4 cases, 2.1%), contrasting with EBV-associated hematological malignancy, which frequently carries large deletions.CONCLUSIONSThis study is the first to uncover the genomic variations of EBV in GC. While EBV is definitively linked to GC, the characteristics of its genomes do not strongly correlate with disease development or progression. Our findings on viral genomes supplement the current understanding of human genomes in EBVaGC.

14 Nov 2024·Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[Early cellular immune exhaustion in patients with Epstein-Barr virus activation following haploidentical hematopoietic stem cell transplantation].

Article

Author: Huang, F ; He, J B ; Xu, N ; Xue, R T ; Lin, R ; Zhou, Y ; Liu, Q F ; Zhang, S Y ; Huang, Y F ; Fan, Z P ; Sun, J

Objective: This study aimed to investigate the association between early immune reconstitution and Epstein-Barr virus (EBV) reactivation by analyzing changes in natural killer (NK), B, and T cells and their functional status in the peripheral blood during the early post-transplant period. Methods: This study included 23 patients who underwent haplo-hematopoietic stem cell transplantation (HSCT). The immune reconstitution of NK cells, T cells, and B cells as well as the expression levels of NK and T cell exhaustion markers (PD-1, TIM-3, and CTLA-4) and cytotoxic function at 1, 2, and 3 months post-transplantation were compared between patients with EBV activation (EBV+ group) and those without activation (EBV- group) post- transplantation. Results: EBV activation occurred in nine patients post-transplantation (EBV+ group), whereas 14 patients demonstrated no activation (EBV- group). All patients with EBV activation exhibited EBV viremia, and no EBV-associated diseases occurred. No significant differences in the clinical characteristics were found between the two groups of patients. The median proportion of CD3(+)CD8(+) T cells in the EBV+ group was significantly lower than that in the EBV- group at 1 month post-transplantation (P=0.033). The median proportion of the CD3(-)CD16(neg)CD56(bri) subset in the EBV+ group was significantly higher than that in the EBV- group at 2 months post-transplantation (P=0.046). No significant differences in the median proportions of CD3(-)CD19(+) B cells were observed between the two groups at 1, 2, and 3 months post-transplantation. The expression of CTLA-4 on CD3(-)CD16(bri)CD56(dim) NK cells in the EBV+ group was significantly higher than that in the EBV- group at 1 month post-transplantation (P=0.033). The expression of TIM-3 on CD3(+)CD8(+) T cells in the EBV+ group was significantly higher than that in the EBV- group (P=0.009). The expression level of TIM-3 on CD3(-)CD16(neg)CD56(dim) NK cells in the EBV+ group was significantly lower than that in the EBV- group at 2 months post-transplantation (P=0.023). The expression levels of TIM-3 on CD3(+)CD4(+) T cells in the EBV+ group than those in the EBV- group at 1 and 3 months post-transplantation (P=0.002, P=0.043). The median positive rate of Granzyme B expression in CD3(+)CD8(+) T cells and CD3(+)CD4(+) T cells in the EBV+ group was significantly lower than that in the EBV- group at 1-month post-transplantation (P=0.033, P=0.016). The median positive rate of Granzyme B expression in the CD3(-)CD16(bri)CD56(neg) cell subset in the EBV+ group was higher than that in the EBV- group at 2 months post-transplantation (P=0.012). The median positive rate of Granzyme B expression in CD3(+)CD4(+) T cells in the EBV+ group remained significantly lower than that in the EBV- group at 2 months post-transplantation (P=0.049). The median positive rate of perforin expression in the CD3(-)CD16(bri)CD56(dim) cell subset was significantly higher in the EBV+ group than in the EBV- group at 3 months post-transplantation (P=0.003). The median positive rate of IFN-γ expression in CD3(+)CD8(+) T cells in the EBV+ group was significantly lower than that in the EBV- group at 3 months post-transplantation (P=0.036) . Conclusion: Delayed NK cell and T lymphocyte reconstitution, high exhaustion marker expression, and weakened cytotoxic functions may be related to EBV reactivation after haploidentical HSCT.

01 Nov 2024·Journal of Pediatric Hematology/Oncology

Pediatric Plasmablastic Lymphoma in the Setting of CD70 Deficiency

Article

Author: Baskin, Kubra ; Vural, Ozge ; Pinarli, Faruk Guclu ; Uyar Gocun, Pinar ; Okur, Arzu ; Dogu, Figen ; Haskologlu, Sule ; Ikinciogullari, Aydan ; Erman, Baran

Combined immunodeficiency due to CD70 deficiency is characterized by increased susceptibility to infections, hypogammaglobulinemia, and malignancy. These patients typically present with chronic Epstein Barr virus (EBV) viremia, severe EBV-related hemophagocytic lymphohistiocytosis, lymphoproliferation, and Hodgkin and non-Hodgkin lymphomas. Plasmablastic lymphoma (PBL) is an extremely rare malignancy in all ages and is predominantly seen in male adults with human immunodeficiency virus infection. EBV infection, immunosuppression, solid organ transplantation, and age-related immune deterioration are also suspected causes of PBL. Nevertheless, there is scarce data about its association with primary immunodeficiencies in the literature. Here, we present the first case of a CD70-deficient pediatric patient with PBL.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

EBV viremia

Basic Info

Related

Analysis